MTVA
MetaVia Inc.
Price Chart
Latest Quote
$1.54
-0.03 (-1.91%)
Current Price
| Previous Close | $1.57 |
| Open | $1.50 |
| Day High | $1.64 |
| Day Low | $1.50 |
| Volume | 514,123 |
Stock Information
| Shares Outstanding | 5.16M |
| Total Debt | $194K |
| Cash Equivalents | $13.73M |
| Net Income | $-13.12M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.95M |
| EPS (TTM) | $-4.21 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-5.59M |
| Income | $-13.12M |
| Book/sh | $1.76 |
| Cash/sh | $2.66 |
| Employees | 8 |
Financial Ratios
| Quick Ratio | 2.65 |
| Current Ratio | 2.73 |
| Debt/Eq | 2.14 |
Returns & Margins
| ROA | -65.28% |
| ROE | -195.12% |
Ownership
| Insider Ownership | 36.50% |
| Institutional Ownership | 13.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.88 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $19.33 |
Technical Indicators
| SMA20 | $2.25 |
| SMA50 | $1.85 |
| SMA200 | $5.34 |
| RSI | 16.95 |
| ATR | 0.2849 |
| Shares Float | 3.38M |
| Short Float | 12.06% |
| Short Ratio | 0.04 |
| Volatility | 0.90 |
| Rel Volume | 0.29 |
Performance History
| Week | -9.94% |
| Month | -46.34% |
| Quarter | +5.48% |
| 6 Months | -81.45% |
| YTD | -83.89% |
| Year | -79.29% |
| 3 Years | -96.46% |
| 5 Years | -99.98% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $1.54 | 516,600 |
| 2026-06-22 | $1.57 | 229,900 |
| 2026-06-18 | $1.60 | 181,700 |
| 2026-06-17 | $1.71 | 196,700 |
| 2026-06-16 | $1.65 | 186,300 |
| 2026-06-15 | $1.71 | 812,300 |
| 2026-06-12 | $1.74 | 586,200 |
| 2026-06-11 | $2.01 | 473,800 |
| 2026-06-10 | $1.96 | 250,500 |
| 2026-06-09 | $1.89 | 920,300 |
| 2026-06-08 | $2.22 | 1,639,500 |
| 2026-06-05 | $2.57 | 15,962,400 |
| 2026-06-04 | $2.45 | 496,900 |
| 2026-06-03 | $2.68 | 339,000 |
| 2026-06-02 | $2.71 | 915,300 |
| 2026-06-01 | $2.73 | 545,600 |
| 2026-05-29 | $2.84 | 1,041,600 |
| 2026-05-28 | $3.10 | 1,166,900 |
| 2026-05-27 | $3.34 | 5,555,200 |
| 2026-05-26 | $2.97 | 3,375,500 |
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $13,708,000 | $28,809,000 | $15,886,000 | $11,418,000 |
| Other Income Expense | $225,000 | $297,000 | $2,955,000 | $-358,000 |
| Net Non Operating Interest Income Expense | $510,000 | $920,000 | $461,000 | $-2,191,000 |
| Operating Expense | $13,708,000 | $28,809,000 | $15,886,000 | $11,418,000 |
| General And Administrative Expense | $6,906,000 | $7,256,000 | $6,728,000 | $8,640,000 |
| Total Other Finance Cost | - | $-920,000 | $-461,000 | - |
| Interest Expense | - | - | $0 | $2,191,000 |
| Interest Expense Non Operating | - | - | $0 | $2,191,000 |
| Other Non Operating Income Expenses | - | - | - | $-83,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Net Interest Income | $510,000 | $920,000 | $461,000 | $-2,191,000 |
| Interest Income | $510,000 | $920,000 | $461,000 | $0 |
| Normalized Income | $-13,198,000 | $-27,889,000 | $-15,425,000 | $-13,692,000 |
| Net Income From Continuing And Discontinued Operation | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Total Operating Income As Reported | $-13,708,000 | $-28,809,000 | $-15,886,000 | $-19,628,000 |
| Net Income Common Stockholders | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Net Income | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Net Income Including Noncontrolling Interests | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Net Income Continuous Operations | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Pretax Income | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Interest Income Non Operating | $510,000 | $920,000 | $461,000 | $0 |
| Operating Income | $-13,708,000 | $-28,809,000 | $-15,886,000 | $-11,418,000 |
| Special Income Charges | - | - | $0 | $-8,210,000 |
| Per Share | ||||
| Diluted EPS | $-7.35 | $-39.16 | $-27.06 | $-477.84 |
| Basic EPS | $-7.35 | $-39.16 | $-27.06 | $-477.84 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,914,000 | $-29,086,000 | $-18,835,000 | $-11,481,000 |
| Total Unusual Items | $225,000 | $297,000 | $2,955,000 | $-275,000 |
| Total Unusual Items Excluding Goodwill | $225,000 | $297,000 | $2,955,000 | $-275,000 |
| Reconciled Depreciation | $19,000 | $20,000 | $6,000 | $20,000 |
| EBITDA (Bullshit earnings) | $-13,689,000 | $-28,789,000 | $-15,880,000 | $-11,756,000 |
| EBIT | $-13,708,000 | $-28,809,000 | $-15,886,000 | $-11,776,000 |
| Diluted Average Shares | $1,766,026 | $705,193 | $461,009 | $29,245 |
| Basic Average Shares | $1,766,026 | $705,193 | $461,009 | $29,245 |
| Diluted NI Availto Com Stockholders | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $225,000 | $297,000 | $2,955,000 | $7,935,000 |
| Research And Development | $6,802,000 | $21,553,000 | $9,158,000 | $2,778,000 |
| Selling General And Administration | $6,906,000 | $7,256,000 | $6,728,000 | $8,640,000 |
| Other Gand A | $5,109,000 | $5,597,000 | $6,728,000 | $8,640,000 |
| Salaries And Wages | $1,797,000 | $1,659,000 | - | - |
| Other Special Charges | - | - | - | $8,210,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Total Assets | $11,123,000 | $16,260,000 | $22,781,000 | $33,534,000 |
| Total Non Current Assets | $248,000 | $188,000 | $269,000 | $2,000 |
| Other Non Current Assets | $21,000 | $21,000 | $21,000 | - |
| Current Assets | $10,875,000 | $16,072,000 | $22,512,000 | $33,532,000 |
| Other Current Assets | $7,000 | $5,000 | $77,000 | $168,000 |
| Current Deferred Assets | $511,000 | $0 | - | - |
| Prepaid Assets | $79,000 | $50,000 | $77,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $10,278,000 | $16,017,000 | $22,435,000 | $33,364,000 |
| Cash And Cash Equivalents | $10,278,000 | $16,017,000 | $22,435,000 | $33,364,000 |
| Cash Financial | $10,278,000 | $16,017,000 | $22,435,000 | $33,364,000 |
| Debt | ||||
| Total Debt | $210,000 | $136,000 | $203,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $142,000 | $58,000 | $136,000 | $0 |
| Current Debt And Capital Lease Obligation | $68,000 | $78,000 | $67,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,790,000 | $8,329,000 | $6,096,000 | $11,784,000 |
| Total Non Current Liabilities Net Minority Interest | $142,000 | $58,000 | $136,000 | $0 |
| Current Liabilities | $5,648,000 | $8,271,000 | $5,960,000 | $11,784,000 |
| Other Current Liabilities | $285,000 | $416,000 | $824,000 | $10,796,000 |
| Payables And Accrued Expenses | $4,466,000 | $7,064,000 | $4,951,000 | $988,000 |
| Payables | $4,372,000 | $5,351,000 | $1,610,000 | $708,000 |
| Accounts Payable | $1,060,000 | $3,879,000 | $821,000 | $708,000 |
| Equity | ||||
| Common Stock Equity | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Total Equity Gross Minority Interest | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Stockholders Equity | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Retained Earnings | $-148,830,000 | $-135,857,000 | $-108,265,000 | $-95,795,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $0 |
| Other Equity Adjustments | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $2,308,294 | $785,193 | $446,002 | $289,045 |
| Share Issued | $2,308,294 | $785,193 | $446,002 | $289,045 |
| Tangible Book Value | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Invested Capital | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Working Capital | $5,227,000 | $7,801,000 | $16,552,000 | $21,748,000 |
| Capital Lease Obligations | $210,000 | $136,000 | $203,000 | $0 |
| Total Capitalization | $5,333,000 | $7,931,000 | $16,685,000 | $21,750,000 |
| Additional Paid In Capital | $154,161,000 | $143,787,000 | $124,945,000 | $117,520,000 |
| Capital Stock | $2,000 | $1,000 | $5,000 | $25,000 |
| Common Stock | $2,000 | $1,000 | $5,000 | $25,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $142,000 | $58,000 | $136,000 | $0 |
| Current Capital Lease Obligation | $68,000 | $78,000 | $67,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $829,000 | $713,000 | $118,000 | - |
| Current Accrued Expenses | $94,000 | $1,713,000 | $3,341,000 | $280,000 |
| Dueto Related Parties Current | $3,312,000 | $1,472,000 | $789,000 | $0 |
| Net PPE | $227,000 | $167,000 | $248,000 | $2,000 |
| Accumulated Depreciation | $-73,000 | $-54,000 | $-34,000 | $-28,000 |
| Gross PPE | $300,000 | $221,000 | $282,000 | $30,000 |
| Other Properties | $210,000 | $133,000 | $202,000 | - |
| Machinery Furniture Equipment | $90,000 | $88,000 | $80,000 | $30,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,703,000 | $-24,718,000 | $-10,849,000 | $-11,712,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,701,000 | $-24,710,000 | $-10,799,000 | $-11,712,000 |
| Cash Flow From Continuing Operating Activities | $-15,701,000 | $-24,710,000 | $-10,799,000 | $-11,712,000 |
| Operating Gains Losses | $-225,000 | $-297,000 | $-2,955,000 | $-5,669,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,000 | $-8,000 | $-50,000 | - |
| Investing Cash Flow | $-2,000 | $-8,000 | $-50,000 | $8,000 |
| Cash Flow From Continuing Investing Activities | $-2,000 | $-8,000 | $-50,000 | $8,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $11,208,000 | $19,998,000 | $0 | $32,250,000 |
| Financing Cash Flow | $9,964,000 | $18,300,000 | $-80,000 | $28,681,000 |
| Cash Flow From Continuing Financing Activities | $9,964,000 | $18,300,000 | $-80,000 | $28,681,000 |
| Net Other Financing Charges | $-1,250,000 | $-1,699,000 | $-80,000 | $-3,569,000 |
| Net Common Stock Issuance | $11,208,000 | $19,998,000 | $0 | $32,250,000 |
| Common Stock Issuance | $11,208,000 | $19,998,000 | $0 | $32,250,000 |
| Net Preferred Stock Issuance | - | - | $0 | $32,250,000 |
| Preferred Stock Issuance | - | - | $0 | $32,250,000 |
| Other | ||||
| End Cash Position | $10,278,000 | $16,017,000 | $22,435,000 | $33,364,000 |
| Beginning Cash Position | $16,017,000 | $22,435,000 | $33,364,000 | $16,387,000 |
| Changes In Cash | $-5,739,000 | $-6,418,000 | $-10,929,000 | $16,977,000 |
| Proceeds From Stock Option Exercised | $6,000 | $1,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-2,000 | $-8,000 | $-50,000 | $8,000 |
| Purchase Of PPE | $-2,000 | $-8,000 | $-50,000 | $0 |
| Change In Working Capital | $-2,930,000 | $2,617,000 | $4,397,000 | $-1,168,000 |
| Change In Payables And Accrued Expense | $-2,388,000 | $2,597,000 | $4,327,000 | $-1,232,000 |
| Change In Accrued Expense | $431,000 | $-461,000 | $4,214,000 | $-1,030,000 |
| Change In Payable | $-2,819,000 | $3,058,000 | $113,000 | $-202,000 |
| Change In Account Payable | $-2,819,000 | $3,058,000 | $113,000 | $-202,000 |
| Change In Prepaid Assets | $-542,000 | $20,000 | $70,000 | $64,000 |
| Other Non Cash Items | $-3,000 | $4,000 | $1,000 | $8,218,000 |
| Stock Based Compensation | $411,000 | $538,000 | $222,000 | $854,000 |
| Depreciation Amortization Depletion | $19,000 | $20,000 | $6,000 | $20,000 |
| Depreciation And Amortization | $19,000 | $20,000 | $6,000 | $20,000 |
| Depreciation | $19,000 | $20,000 | $6,000 | $20,000 |
| Gain Loss On Investment Securities | $-225,000 | $-297,000 | $-2,955,000 | $-5,744,000 |
| Net Income From Continuing Operations | $-12,973,000 | $-27,592,000 | $-12,470,000 | $-13,967,000 |
| Sale Of PPE | - | - | $0 | $8,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $75,000 |
| Effect Of Exchange Rate Changes | - | - | - | $0 |
Fetched: 2026-06-22